^
    Apply
    Phase I Study of APX005M in Pediatric Central Nervous System Tumors (NCT03389802)
    Phase 1
    Pediatric Brain Tumor Consortium
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    03/01/2018
    Primary completion :
    09/30/2023
    Completion :
    06/30/2025
    TMB • TNFA • CXCL8 • CD4
    |
    sotigalimab (PYX-107)
    APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma (NCT03502330)
    Phase 1
    Yale University
    Completed
    Last update posted :
    07/03/2024
    Initiation :
    06/09/2018
    Primary completion :
    01/05/2022
    Completion :
    05/15/2024
    PD-L1 • BRAF • CD8 • IFNG • CD163 • IL10 • CD40LG
    |
    EGFR mutation • EGFR T790M • ALK rearrangement
    |
    Opdivo (nivolumab) • cabiralizumab (BMS-986227) • sotigalimab (PYX-107)
    Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer (NCT02600949)
    Phase 1
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    05/11/2016
    Primary completion :
    05/31/2025
    Completion :
    05/31/2025
    CEACAM5
    |
    Keytruda (pembrolizumab) • Zyclara (imiquimod) • sotigalimab (PYX-107)
    APX005M and Doxorubicin in Advanced Sarcoma (NCT03719430)
    Phase 2
    Alexander Z. Wei, MD
    Active, not recruiting
    Last update posted :
    03/08/2024
    Initiation :
    03/20/2019
    Primary completion :
    12/31/2024
    Completion :
    12/31/2025
    CD40
    |
    doxorubicin hydrochloride • sotigalimab (PYX-107)
    CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab (NCT03123783)
    Phase 1/2
    Apexigen America, Inc.
    Completed
    Last update posted :
    12/25/2023
    Initiation :
    07/10/2017
    Primary completion :
    11/16/2020
    Completion :
    11/16/2020
    EGFR • BRAF • ALK
    |
    EGFR mutation • BRAF mutation
    |
    Opdivo (nivolumab) • sotigalimab (PYX-107)
    Study of the CD40 Agonistic Monoclonal Antibody APX005M (NCT02482168)
    Phase 1
    Apexigen America, Inc.
    Completed
    Last update posted :
    12/20/2023
    Initiation :
    05/01/2015
    Primary completion :
    06/13/2018
    Completion :
    06/19/2018
    MSI
    |
    MSI-H/dMMR
    |
    sotigalimab (PYX-107)